A Pancreatic Cancer Organoid Platform Identifies an Inhibitor Specific to Mutant KRAS

Scientists reported a high-throughput drug-screening platform using a series of isogenic murine pancreatic organoids that were wild type or contain common PDAC driver mutations, representing both classical and basal PDAC phenotypes.